Roivant Sciences (ROIV) Non Operating Income (2021 - 2022)
Roivant Sciences' (ROIV) quarterly Non Operating Income came in at $18.1 million in Q4 2022, up 537.6% on a YoY basis from $2.8 million in Q4 2021, and up 404.12% quarter-over-quarter from -$5.9 million in Q3 2022.
Powered by 
Analysis
Roivant Sciences (ROIV) Non Operating Income (2021 - 2022) Analysis & Trends
Roivant Sciences (ROIV) has reported Non Operating Income for 2 consecutive years, with $18.1 million the latest figure, recorded in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.75 Bn | 26.59 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 18.10 Mn |
| Sep 30, 2022 | -5.95 Mn |
| Dec 31, 2021 | 2.84 Mn |
| Sep 30, 2021 | -2.20 Mn |